Birth Outcomes in Women Who Have Taken Vedolizumab in Pregnancy: Results From the Vedolizumab Pregnancy Exposure Registry
No significant increased risks were noted with vedolizumab exposure for any of the other study outcomes. These data add reassuring evidence in support of the safety of vedolizumab in pregnancy.
Authors
- Christina Chambers (ORCID: https://orcid.org/0000-0003-4675-7722)
- Kenneth Lyons Jones (ORCID: https://orcid.org/0000-0002-5404-5912)
- Yunjun Luo
- Stephen R. Braddock (ORCID: https://orcid.org/0000-0002-7990-8630)
- Margaret P Adam (ORCID: https://orcid.org/0000-0001-9817-5121)
- Ronghui Xu (ORCID: https://orcid.org/0000-0002-2822-0561)
- Diana L. Johnson
Institutions
- University of San Diego (US)
- University of Washington (US)
- University of Missouri–St. Louis (US)
- University of California San Diego (US)
- Human Longevity (United States) (US)
- Saint Louis University (US)
Publication Details
- Journal
- The American Journal of Gastroenterology
- Published
- 2025-06-11
- DOI
- https://doi.org/10.14309/ajg.0000000000003593
- Citations
- 3
- Primary Topic
- Pregnancy and Medication Impact
- Type
- article
- Field-Weighted Citation Impact
- 5.64